Voniza10 mg

Voniza 10 mg is used for the treatment and prevention of acid-related stomach conditions, including gastric ulcer, duodenal ulcer, and reflux esophagitis. It also helps prevent ulcer recurrence in patients taking low-dose aspirin or NSAIDs.

It is additionally used as part of Helicobacter pylori (H. pylori) eradication therapy, supporting recovery in conditions such as peptic ulcers, MALT lymphoma, idiopathic thrombocytopenic purpura (ITP), and post-endoscopic resection of early gastric cancer or H. pylori–associated gastritis.

Potassium competitive acid blocker

Voniza 10 mg is a potassium-competitive acid blocker (P-CAB) that suppresses gastric acid secretion by reversibly inhibiting the H⁺/K⁺-ATPase enzyme in parietal cells. Unlike proton pump inhibitors, it does not require acid activation and acts directly at the site of acid production.

Due to its strong basic nature and prolonged retention in gastric parietal cells, Voniza 10 mg provides rapid, sustained, and potent acid suppression, helping protect the gastric mucosa and reduce upper gastrointestinal mucosal damage effectively.

The dose of Voniza 10 mg (Voniza 10 mg) varies depending on the condition being treated. It is administered orally once or twice daily, as prescribed by a physician.

Gastric Ulcer

• Adult dose: 20 mg once daily
• Duration: Usually 8 weeks

Duodenal Ulcer

• Adult dose: 20 mg once daily
• Duration: Usually 6 weeks

Reflux Esophagitis

• Treatment dose: 20 mg once daily for 4 weeks
• If response is insufficient, treatment may be extended up to 8 weeks

Maintenance Therapy

• Dose: 10 mg once daily
• May be increased to 20 mg once daily if needed

Prevention of Ulcer Recurrence (Low-Dose Aspirin Use)

• Dose: 10 mg once daily

Prevention of NSAID-Induced Ulcers

• Dose: 10 mg once daily

Helicobacter pylori Eradication (Triple Therapy)

• Duration: 7 days, twice daily regimen
• Components per dose:
  • Voniza 10 mg 20 mg
  • Amoxicillin 750 mg
  • Clarithromycin 200 mg (may be increased up to 400 mg twice daily if required)

Second-Line H. pylori Eradication Therapy

• Duration: 7 days, twice daily regimen
• Components per dose:
  • Voniza 10 mg 20 mg
  • Amoxicillin 750 mg
  • Metronidazole 250 mg

Voniza 10 mg can be taken without regard to food or timing of food.

Voniza 10 mg is contraindicated in:

• Patients with hypersensitivity to Voniza 10 mg or to any excipient of the product.
• Patients receiving atazanavir sulphate, nelfinavir or rilpivirine hydrochloride

Like all medicines, Voniza 10 mg (Voniza 10 mg) may cause side effects, although not everyone experiences them.

Common Side Effects

• Diarrhea
• Constipation
• Nausea
• Abdominal distension (bloating)
• Edema (swelling)

Allergic Reactions

• Drug hypersensitivity reactions
• Skin rash, drug eruption, and urticaria (hives)
• Rare cases of anaphylactic shock

Liver-Related Effects

Some patients may experience changes in liver function tests, including:

• Increased AST, ALT, ALP, LDH, and GGT (y-GPT)
• Abnormal liver function tests
• Hepatotoxicity
• Jaundice (yellowing of skin or eyes)

Blood & Other Effects

• Eosinophilia (increased eosinophil count)

Important Note

Most side effects are mild to moderate, but serious allergic reactions or liver problems require immediate medical attention and discontinuation of the medicine.

There is limited clinical experience with Voniza 10 mg (Voniza 10 mg) overdose. No specific pattern of severe toxicity has been established.

Management of Overdose

• Voniza 10 mg is not removed by hemodialysis
• If overdose occurs, treatment should be symptomatic and supportive, based on the patient’s clinical condition

Important Note

Patients suspected of overdose should be monitored closely and managed in a healthcare facility for appropriate supportive care.

Store below 30°C, in a cool and dry place. Keep away from light. Keep all the medicine out of the reach of children.

Elderly Patients

In elderly patients, hepatic and renal functions may be reduced, so Voniza 10 mg should be used with caution and careful clinical monitoring.

Pediatric Use (<18 years)

• The safety and efficacy have not been established in children and adolescents
• Therefore, use of Voniza 10 mg is not recommended under 18 years of age

Renal Impairment

• Mild to moderate renal impairment (eGFR 30–89 mL/min): No dose adjustment required
• Severe renal impairment (eGFR <30 mL/min): Use should be avoided

Hepatic Impairment

• Mild hepatic impairment (Child-Pugh A): No dose adjustment required
• Moderate to severe hepatic impairment (Child-Pugh B or C): Use should be avoided

Store below 30°C, in a cool and dry place. Keep away from light. Keep all the medicine out of the reach of children.